Skip to content

Clinical trials

Phase 3 Amyloidosis trials in Japan

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Amyloidosis Phase: Phase 3 Country / region: Japan Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20132
20151
20161
20171
20192
20201
20211
20221
20231
20241
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting4
Active, not recruiting2
Enrolling by invitation1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alnylam Pharmaceuticals6
Ionis Pharmaceuticals, Inc.2
Pfizer2
Alexion Pharmaceuticals, Inc.1
Eidos Therapeutics, a BridgeBio company1
Intellia Therapeutics1
Janssen Research & Development, LLC1
Prothena Biosciences Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Amyloidosis15
Cardiomyopathies6
Amyloid Neuropathies, Familial5
Alzheimer Disease3
Amyloidosis, Familial3
Polyneuropathies2
Amyloid Neuropathies1
Heart Diseases1

Trials

Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.